Related Experiment Video

Updated: Sep 30, 2026

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction

Kathryn Bates1, Charles E Ruggeroli, Steven Goldman

  • 1Cardiology Section, Southern Arizona Veterans Administration Health Care System, Tucson, AZ 85723, USA.

American Journal of Physiology. Heart and Circulatory Physiology
|July 19, 2002
PubMed

Insights

Simvastatin treatment improved blood vessel function in rats with heart failure by increasing nitric oxide (NO) production. This study shows simvastatin restores NO-dependent vasorelaxation and boosts endothelial NO synthase (eNOS) protein levels.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Congestive heart failure (CHF) post-myocardial infarction impairs endothelial nitric oxide (NO)-mediated vasorelaxation.
  • Statins, like simvastatin, may influence vascular tone independently of lipid-lowering effects.

Purpose of the Study:

  • To investigate if simvastatin can restore NO-dependent vasorelaxation in CHF.
  • To determine the effect of simvastatin on endothelial nitric oxide synthase (eNOS) protein expression in CHF.

Main Methods:

  • Incubation of rat aorta and cultured endothelial cells with simvastatin.
  • Assessment of acetylcholine (ACh)-mediated vasorelaxation.
  • Quantification of eNOS protein content using Western blot analysis.
  • In vivo study using a rat coronary artery ligation model of CHF.

Main Results:

  • Simvastatin enhanced ACh-mediated vasorelaxation in normal rat aorta and in CHF arterial rings.
  • Simvastatin significantly increased eNOS protein content in both isolated tissues and cultured cells.
  • In vivo, simvastatin reduced mean arterial pressure and improved cardiac function in CHF rats.
  • The beneficial effects of simvastatin on vasorelaxation were abolished by inhibiting NO generation.

Conclusions:

  • Chronic simvastatin treatment restores endothelial NO-dependent dysfunction in CHF.
  • Simvastatin upregulates eNOS protein content in arterial tissue, contributing to improved vasorelaxation.
  • These findings suggest simvastatin has direct vascular benefits in heart failure beyond lipid reduction.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography09:47

Measurement of Endothelium-Dependent Vasorelaxation in the Mouse Thoracic Aorta Using Tensometric Small Volume Chamber Myography

Published on: August 12, 2022

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...